David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
Expert Opin Pharmacother. 2010 Aug;11(12):2077-85. doi: 10.1517/14656566.2010.499358.
Chronic obstructive pulmonary disease (COPD) is a partially reversible, progressive obstructive disorder. Bronchodilators are the mainstay of treatment since they improve lung function and patient-reported outcomes and reduce acute exacerbations. Long-acting inhaled bronchodilators (at present including the once-daily antimuscarinic tiotropium, and the twice-daily beta(2)-agonists formoterol and salmeterol) are recommended as first-line treatment for patients with persistent symptoms. Indacaterol maleate has been developed as a new once-daily inhaled beta(2)-selective agonist.
This article reviews the published literature on the pharmacologic properties and the Phase II and III trials that have evaluated the safety and efficacy of this new agent.
The reader will obtain an appreciation of the safety and efficacy of indacaterol and the role that it might play in the future management of COPD of varying severity.
Indacaterol is a new, once-daily beta(2)-agonist with an onset of action within 5 min and a duration of bronchodilation of at least 24 h. In doses of 150 and 300 microg, it has sustained benefits over 6 - 12 months with respect to both bronchodilation and patient-reported outcomes and is well-tolerated with an acceptable safety profile.
慢性阻塞性肺疾病（COPD）是一种部分可逆的、进行性的阻塞性疾病。支气管扩张剂是治疗的主要手段，因为它们可以改善肺功能和患者报告的结果，并减少急性加重。长效吸入型支气管扩张剂（目前包括每日一次的抗毒蕈碱药噻托溴铵，以及每日两次的β2-激动剂福莫特罗和沙美特罗）被推荐作为持续性症状患者的一线治疗药物。马来酸茚达特罗已被开发为一种新的每日一次吸入型β2-选择性激动剂。
本文综述了已发表的关于该药物的药理学特性以及评估该新药物安全性和疗效的 II 期和 III 期临床试验的文献。
读者将了解茚达特罗的安全性和疗效，以及它在未来治疗不同严重程度 COPD 中的作用。
茚达特罗是一种新型的每日一次的β2-激动剂，起效时间在 5 分钟内，支气管扩张作用持续至少 24 小时。在 150 和 300 微克的剂量下，它在 6-12 个月的时间内持续改善支气管扩张和患者报告的结果，并且耐受性良好，安全性可接受。
